Press Release
Open Doors to the Asian Market: Seoul Bio Hub-Celltrion Launches ‘Global Open Innovation’ for U.S. Startups
Seoul Bio Hub and Celltrion Launch Strategic Gateway ‘Global Open Innovation’ to Help U.S. Bio Startups Dominate the Asian Market
Two U.S.-Based Biotech and Medical Device Startups to Be Selected Based on Technology Alignment with Celltrion’s Expertise in Antibodies, Peptides, and Drug Formulation
Seoul, Korea – 17/09/2025 – (SeaPRwire) – Seoul’s bio startup hub ‘Seoul Bio Hub’ and global pharmaceutical leader ‘Celltrion’ have joined forces to launch the ‘2025 Seoul Bio Hub-Celltrion Global Open Innovation (GOI)’ program. This program goes beyond a simple competition, serving as a platform designed to help U.S. startups successfully establish themselves in the Asian market.
This GOI targets U.S.-based bio and medical startups, with companies established within the past 7 years eligible to apply. The recruitment areas encompass all technologies suitable for collaboration with Celltrion, including antibodies, peptides, small molecules, formulations, and cell and gene therapies.
The application deadline is September 30, 2025. The selection process will proceed in the following order:
- Primary document evaluation
- Technology review
- Secondary presentation evaluation.
The two finally selected companies will receive customized follow-up support and gain opportunities to expand into global markets through collaboration with Celltrion, leveraging South Korea’s innovative ecosystem and global capabilities.
A Seoul Bio Hub representative stated, “This program will serve as a bridgehead that goes beyond simple space support, enabling U.S. startups to rapidly grow in the Asian market by leveraging Seoul’s excellent clinical infrastructure and research environment.”
A Celltrion representative announced, “Based on Celltrion’s capabilities and know-how accumulated across the entire pharmaceutical industry process including R&D, production, and sales, we will support promising U.S. startups to successfully enter the Asian market and create synergy with our company.”
South Korea has established itself as a bio hub leading the global market with clear numerical evidence. According to global consulting firm Intralink, South Korea’s biopharmaceutical market is valued at approximately $22 billion, ranking 13th globally.
Additionally, market research firm Grand View Research forecasts that South Korea’s biotechnology market will grow to $81.6 billion (approximately 110 trillion KRW) by 2030, representing an annual average growth rate of 18.3%.
Private investment is also active. From 2020 to 2022, R&D and facility investments recorded an annual average growth rate of 21.6%. This demonstrates that South Korea is not merely a potential market, but a rapidly growing innovation ecosystem.
According to ClinicalTrials.gov, the global clinical trial database, Seoul has consistently maintained a top position among major global cities in the number of new clinical trials over the past decade.
South Korea’s Ministry of Health and Welfare has set ‘Achieving Global 3rd Place in Clinical Trials’ as a policy objective through the ‘3rd Five-Year Plan for the Pharmaceutical and Bio Industry (2023-2027)’. Furthermore, in 2025, it raised a total of over 386.6 billion KRW through the ‘Bio Health Mega Fund’ and is actively supporting innovative companies’ clinical trials and commercialization through the national integrated bio big data construction project and AI, bio health regulatory regulatory sandboxes.
Seoul Bio Hub is a bio startup support organization established by Seoul City in 2017. It provides 251 pieces of shared laboratory equipment and affordable tenant space at 10% of the cost compared to major areas in Seoul. As of May 2025, it has supported 322 startups and attracted a total of 576 billion KRW in follow-up investment, proving its potential for success.
Celltrion is South Korea’s global comprehensive biotechnology company that developed the world’s first antibody biosimilar ‘Remsima’. The company performs the entire process from research and development to approval, production, and sales, supplying high-quality biopharmaceuticals to over 100 countries worldwide. Based on world-class research and production infrastructure, it contributes to expanding global access to pharmaceuticals and continues to support and collaborate with promising startups through active open innovation strategies.
For detailed information regarding program applications and inquiries, please access LinkedIn, search for ‘Seoul Bio Hub’, and check the 「2025 Seoul Bio Hub-Celltrion Global Open Innovation」 recruitment announcement posted on the official company page.
About Seoul Bio Hub
https://www.seoulbiohub.kr/front/user/engmain.do
Establishment Date: October 30, 2017
Operating Entity: Established by Seoul City / Joint operation by KIST and Korea University
Location: 117-3 Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea
Purpose: Growth and commercialization support for early-stage bio and healthcare startups under 10 years
Tenant Companies (As of June 2025): Total 126 companies (Digital Health 42 companies (33.3%), Pharmaceuticals 61 companies (48.5%), Medical Devices 23 companies (18.2%))
Infrastructure: Laboratories, office spaces, meeting rooms, conference rooms, research equipment (249 devices, 109 types, approximately $8 million scale)
Research and Human Resource Network (Regional): Approximately 7,000 PhD-level personnel, approximately 120,000 university students, $1.13 billion in research funding, connections with 12 universities and research institutions and 7 hospitals
Major Support Programs:
- IR matching and investment linkage
- Expert consulting and CEO education
- Hospital-linked clinical and data programs
- Open innovation with domestic and international pharmaceutical companies
About Celltrion
https://www.celltrion.com/en-us
Establishment Date: February 26, 2002
Location (Headquarters): 23 Academy-ro, Yeonsu-gu, Incheon Metropolitan City, Republic of Korea
Business Areas and Major Products (Services)
Possessing Differentiated Integrated Solutions Across the Entire Biopharmaceutical Business Process
- Remsima: World’s first monoclonal antibody biosimilar (TNF-α inhibitor)
- Herzuma: Trastuzumab biosimilar for breast and gastric cancer treatment
- Truxima (CT-P10): Rituximab biosimilar (lymphoma, rheumatoid arthritis, etc.)
- Multiple products including Zymfentra, Yuflyma, Vegzelma, Steqeyma, Avtozma are under global approval and commercialization
No of Employees: Approx. 3,003 (As of June 30, 2025)
Media Contact
Brand: SEOUL BIO HUB
Contact: Lee Yoon Jin
Phone: +82 02-2200-3345
Email: lynj@kist.re.kr
Website: (KOR) https://www.seoulbiohub.kr/front/user/main.do;
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Shibo Unveils Next Phase of Web3 Impact With Doginal Dogs and Global Events
Chicago USA, 17th September 2025, ZEX PR WIRE, Shibo is launching the next phase of his impact across NFTs, crypto communities, and real-world cultural events. Shibo has co-founded Doginal Dogs, a popular NFT project. At this point, he is entering a new phase to drive the convergence of blockchain, entertainment, and philanthropy.
A New Recipe to Change Web3
Shibo has built a strong presence on X (Twitter). Here, his daily Spaces draw more than 20,000 listeners and generate millions of impressions each week. These talks cover changes in culture, community, and the market in Web3.
The attention around these Spaces has grown thanks to the regular involvement of well-known people from business and entertainment. These Spaces are now where mainstream culture and blockchain innovation meet.
Shibo’s co-creation of Doginal Dogs has attracted the curiosity of many. The operation made him one of the top builders in the NFT field. People often compare the project to CryptoPunks because of its cultural significance. It has now grown into a community with a floor price of over $5,000. It shows that NFTs are becoming more than just digital assets. These tokens are also symbols of identity, community, and cultural history in the crypto world.
Crypto and Mainstream Culture
Shibo has always worked to make Web3 more than just online communities. He has had famous people from all over the world on his Twitter/X Spaces. The list includes Grant Cardone, Jason Derulo, and many more. Shibo connects mainstream entertainment with blockchain culture by bringing in A-list celebrities. This helps keep crypto in the news around the world.
Shibo has been working to bring crypto culture into real life, going beyond internet memes. He has put on big events – such as DDVEGAS and DDNYC – at important venues. The location list includes TAO Group, The Venetian, Moxy, and Marriott. These events aim to turn the energy of online communities into real-world impact.
About Shibo
Shibo is a crypto entrepreneur, community leader, and important voice in the Web3 space. He is known as the biggest voice in XRP’s history. Also, he has earned a reputation as a trusted expert in trading, NFTs, and cultural leadership.
He is the co-founder of Doginal Dogs, as mentioned. He is also host of one of the most listened-to Spaces on Twitter/X, and organizer of major real-world events. In this context, Shibo continues to define how crypto intersects with culture, community, and philanthropy.
Shibo’s official website and social media pages below contain more information for anyone interested.
X (Twitter) | Telegram | Discord | Instagram
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Barkmeta Reveals Stellar Progress as New Face of Crypto
New York , USA, 17th September 2025, ZEX PR WIRE, Barkmeta, a well-known crypto leader with a massive online following, has unveiled new details regarding his stellar progress in building a crypto-driven, flourishing community. His project is on course to outperform most other crypto projects through unique innovations and unprecedented social media campaigns.
Barkmeta is a popular influencer in the crypto community. His daily shows help people connect over the power of Web3 and blockchain-based innovations, such as NFTs and DeFi. Barkmeta educates and helps people generate value from crypto projects, promoting assets with the potential to outperform top S&P 500 companies like Nvidia.
Barkmeta’s rise to stardom can be attributed to his substantial background in social media marketing and content creation. Many insiders in these fields have called Barkmeta a branding genius despite initially being regarded as an underdog and “faded.” Nowadays, Barkmeta is the leader of one of the most important projects of the current cycle. He is building the biggest crypto Twitter (now X) community, numbering over 230,000 followers, while hosting some of the largest X spaces daily.
Barkmeta has also attracted the interest and support of prominent and influential actors in the cryptocurrency space and beyond. He is proud to have met and shaken hands with personalities such as Elon Musk, Joe Rogan, Shane Gillis, the Kill Tony crew, Antônio Brown, and many more. Notably, Barkmeta gained access to the most exclusive rooms, such as Donald Trump’s inauguration dinner at Mar-a-Lago.
About Barkmeta
Barkmeta can be considered the new face of crypto due to his solid experience and capacity for innovation. His growing online community brings people from all walks of life to benefit from the latest advances in Web3, crypto, and beyond.
Follow Barkmeta on X and join his promising projects that are already attracting substantial interest and support from investors and crypto enthusiasts.
Learn more about Barkmeta on his official website and social media channels: Telegram, Discord, and Instagram.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
BioLight Launches BioLithin A Breakthrough Mitochondrial Supplement for Energy Muscle Health and Longevity
United States, 17th Sep 2025 – BioLight, an innovative leader in advanced health and longevity solutions, proudly announces the launch of BioLithin, a next-generation mitochondrial supplement designed to strengthen cellular resilience, boost energy, and support long-term vitality.
BioLithin is formulated with a unique combination of Urolithin A, Urolithin B, and Taurine, all carefully selected and dosed based on the latest scientific research. By targeting mitochondrial renewal and optimizing cellular function, BioLithin provides a powerful defense against the natural decline in energy, muscle health, and cognitive function that comes with aging.
A Revolutionary Approach to Mitochondrial Health
Mitochondria, often referred to as the “powerhouses” of the cell, play a vital role in energy production, metabolism, and longevity. As people age, mitochondrial efficiency declines, leading to fatigue, reduced strength, and increased vulnerability to age-related conditions. BioLithin was created to address this challenge directly, helping individuals renew their mitochondrial health from the inside out.
The supplement works through three core mechanisms:
- Mitochondrial Renewal – Promotes recycling and creation of new mitochondria, enhancing energy efficiency and endurance.
- Longevity Defense – Combats inflammation and oxidative damage, two of the biggest contributors to cellular aging.
- Neuroprotection – Activates brain-supportive pathways that help defend against cognitive decline and promote mental clarity.
A Synergistic Blend of Science-Backed Ingredients
What sets BioLithin apart is its groundbreaking combination of Urolithin A, Urolithin B, and Taurine:
- Urolithin A – Shown in clinical studies to support mitochondrial biogenesis and improve muscle endurance, making it a cornerstone in longevity science.
- Urolithin B – A rare, naturally occurring compound that complements Urolithin A, supporting muscle growth and protein synthesis.
- Taurine – A powerful amino acid linked to cellular hydration, heart health, and brain function, recently highlighted in longevity research as essential for healthy aging.
Unlike other supplements that use general extracts, BioLight sources ultra-high purity Urolithins from pomegranate peel—the most efficacious portion of the fruit for delivering these compounds. This ensures that every capsule of BioLithin offers unmatched potency and consistency.
Rooted in Cutting-Edge Research
Every ingredient and dosage in BioLithin is backed by the latest peer-reviewed science. Studies have demonstrated the profound effects of Urolithins on mitochondrial renewal, muscle health, and cognitive vitality. By combining these compounds with Taurine, BioLight has created a supplement that not only supports longevity but also empowers individuals to stay active, resilient, and mentally sharp as they age.
“With BioLithin, we’re taking mitochondrial health to the next level,” said Don Bailey, spokesperson for BioLight. “This product was designed for those who want to maintain peak energy, strength, and cognitive performance throughout their lives. We believe BioLithin represents a new frontier in longevity science, giving people the tools to age better, stronger, and smarter.”
Availability
BioLithin is now available exclusively through the BioLight official website. Customers can explore detailed product information, scientific references, and purchase options directly from the site.
About BioLight
Founded with a mission to advance human longevity through science-based nutrition, BioLight develops innovative supplements that target the root causes of cellular aging. By combining cutting-edge research with high-purity ingredients, BioLight is redefining what’s possible in proactive health and wellness. The company is committed to helping people achieve optimal vitality and resilience at every stage of life.
Media Contact
Organization: BioLight
Contact Person: Don Bailey
Website: https://www.biolight.shop/
Email: Send Email
Country:United States
Release id:34071
Disclaimer: This press release is for informational purposes only and does not constitute medical advice. The product described is a dietary supplement, not intended to diagnose, treat, cure, or prevent any disease. Individuals should consult a qualified healthcare professional before starting any new supplement regimen.
The post BioLight Launches BioLithin A Breakthrough Mitochondrial Supplement for Energy Muscle Health and Longevity appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release1 week ago
Talisman Brings Built-In Crypto AI Agents to the Wallet
-
Press Release7 days ago
Earn $7,700 a day: BJMINING revolutionizes Bitcoin passive income with cloud mining
-
Press Release2 days ago
Software Applications Launches All-in-One Business Management Platform to Simplify Operations for Businesses of All Sizes
-
Press Release1 week ago
Talisman Brings Built-In Crypto AI Agents to the Wallet
-
Press Release7 days ago
Swanson Reed Acquires AusGrant Strengthening Its Position as a Global Leader in R&D and Innovation Funding
-
Press Release7 days ago
How WinnerMining Makes Passive Income from BTC and XRP Simple and Transparent
-
Press Release4 days ago
More Than Metrics: Elliot Ambalo’s Blueprint for Long-Term Brand Loyalty
-
Press Release3 days ago
Rocketta Confirms September 19 Launch Date for Frontier Alpha ETF (in Strategic Deal with Altimor Asset Strategies), Investor Demand Surges Ahead of Trading Window